In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Edward Boudreau will retire from the Columbia Funds board at the end of this year after serving for two years as independent chairman and 14 years ...
In a detailed opinion released this week, a New York judge has explained why he dismissed an excessive fees case against Calamos Advisors. Judge Edgardo Ramos, ...
Susan Wyderko will retire from her position as president and CEO of Mutual Fund Directors Forum in the fall of 2020. When she steps down next ...
Independent mutual fund directors took home more money in 2018, and the boards on which they sit became slightly more diverse, according to new data published ...